158 related articles for article (PubMed ID: 23850805)
1. Sequential decisions on FAS sequencing guided by biomarkers in patients with lymphoproliferation and autoimmune cytopenia.
Rensing-Ehl A; Janda A; Lorenz MR; Gladstone BP; Fuchs I; Abinun M; Albert M; Butler K; Cant A; Cseh AM; Ebinger M; Goldacker S; Hambleton S; Hebart H; Houet L; Kentouche K; Kühnle I; Lehmberg K; Mejstrikova E; Niemeyer C; Minkov M; Neth O; Dückers G; Owens S; Rösler J; Schilling FH; Schuster V; Seidel MG; Smisek P; Sukova M; Svec P; Wiesel T; Gathmann B; Schwarz K; Vach W; Ehl S; Speckmann C
Haematologica; 2013 Dec; 98(12):1948-55. PubMed ID: 23850805
[TBL] [Abstract][Full Text] [Related]
2. FAS-L, IL-10, and double-negative CD4- CD8- TCR alpha/beta+ T cells are reliable markers of autoimmune lymphoproliferative syndrome (ALPS) associated with FAS loss of function.
Magerus-Chatinet A; Stolzenberg MC; Loffredo MS; Neven B; Schaffner C; Ducrot N; Arkwright PD; Bader-Meunier B; Barbot J; Blanche S; Casanova JL; Debré M; Ferster A; Fieschi C; Florkin B; Galambrun C; Hermine O; Lambotte O; Solary E; Thomas C; Le Deist F; Picard C; Fischer A; Rieux-Laucat F
Blood; 2009 Mar; 113(13):3027-30. PubMed ID: 19176318
[TBL] [Abstract][Full Text] [Related]
3. Looking for ALPS: The value of a combined assessment of biochemical markers.
Fernandez I; Touzot F
Pediatr Allergy Immunol; 2024 May; 35(5):e14135. PubMed ID: 38700373
[TBL] [Abstract][Full Text] [Related]
4. Deregulation of Fas ligand expression as a novel cause of autoimmune lymphoproliferative syndrome-like disease.
Nabhani S; Ginzel S; Miskin H; Revel-Vilk S; Harlev D; Fleckenstein B; Hönscheid A; Oommen PT; Kuhlen M; Thiele R; Laws HJ; Borkhardt A; Stepensky P; Fischer U
Haematologica; 2015 Sep; 100(9):1189-98. PubMed ID: 26113417
[TBL] [Abstract][Full Text] [Related]
5. Somatic FAS mutations are common in patients with genetically undefined autoimmune lymphoproliferative syndrome.
Dowdell KC; Niemela JE; Price S; Davis J; Hornung RL; Oliveira JB; Puck JM; Jaffe ES; Pittaluga S; Cohen JI; Fleisher TA; Rao VK
Blood; 2010 Jun; 115(25):5164-9. PubMed ID: 20360470
[TBL] [Abstract][Full Text] [Related]
6. Missense mutations in the Fas gene resulting in autoimmune lymphoproliferative syndrome: a molecular and immunological analysis.
Bettinardi A; Brugnoni D; Quiròs-Roldan E; Malagoli A; La Grutta S; Correra A; Notarangelo LD
Blood; 1997 Feb; 89(3):902-9. PubMed ID: 9028321
[TBL] [Abstract][Full Text] [Related]
7. [Non-malignant, non-infectious lymphoproliferation: challenges in the diagnosis and treatment of autoimmune lymphoproliferative syndrome].
Molnár E; Kovács G; Varga L; Tasnády S; Bors A; Tankó L; Csabán D; Kapócs K; Nemes-Nagy Z; Andrikovics H
Orv Hetil; 2022 Jan; 163(4):123-131. PubMed ID: 35066491
[TBL] [Abstract][Full Text] [Related]
8. Identification of new Fas mutations in a patient with autoimmune lymphoproliferative syndrome (ALPS) and eosinophilia.
Aspinall AI; Pinto A; Auer IA; Bridges P; Luider J; Dimnik L; Patel KD; Jorgenson K; Woodman RC
Blood Cells Mol Dis; 1999; 25(3-4):227-38. PubMed ID: 10575548
[TBL] [Abstract][Full Text] [Related]
9. Identical phenotype in patients with somatic and germline CD95 mutations requires a new diagnostic approach to autoimmune lymphoproliferative syndrome.
Rössler J; Enders A; Lahr G; Heitger A; Winkler K; Fuchs H; Kopp M; Niemeyer C; Ehl S
J Pediatr; 2005 Nov; 147(5):691-4. PubMed ID: 16291365
[TBL] [Abstract][Full Text] [Related]
10. Revisiting autoimmune lymphoproliferative syndrome caused by Fas ligand mutations.
Maccari ME; Schneider P; Smulski CR; Meinhardt A; Pinto F; Gonzalez-Granado LI; Schuetz C; Sica MP; Gross M; Fuchs I; Kury P; Heeg M; Vocat T; Willen L; Thomas C; Hühn R; Magerus A; Lorenz M; Schwarz K; Rieux-Laucat F; Ehl S; Rensing-Ehl A
J Allergy Clin Immunol; 2023 May; 151(5):1391-1401.e7. PubMed ID: 36621650
[TBL] [Abstract][Full Text] [Related]
11. Clinical and immunological overlap between autoimmune lymphoproliferative syndrome and common variable immunodeficiency.
Rensing-Ehl A; Warnatz K; Fuchs S; Schlesier M; Salzer U; Draeger R; Bondzio I; Joos Y; Janda A; Gomes M; Abinun M; Hambleton S; Cant A; Shackley F; Flood T; Waruiru C; Beutel K; Siepermann K; Dueckers G; Niehues T; Wiesel T; Schuster V; Seidel MG; Minkov M; Sirkiä K; Kopp MV; Korhonen M; Schwarz K; Ehl S; Speckmann C
Clin Immunol; 2010 Dec; 137(3):357-65. PubMed ID: 20832369
[TBL] [Abstract][Full Text] [Related]
12. Using biomarkers to predict the presence of FAS mutations in patients with features of the autoimmune lymphoproliferative syndrome.
Caminha I; Fleisher TA; Hornung RL; Dale JK; Niemela JE; Price S; Davis J; Perkins K; Dowdell KC; Brown MR; Rao VK; Oliveira JB
J Allergy Clin Immunol; 2010 Apr; 125(4):946-949.e6. PubMed ID: 20227752
[No Abstract] [Full Text] [Related]
13. Lack of Fas and Fas-L mutations in patients with lymphoproliferative disorders associated with Sjögren's syndrome and type II mixed cryoglobulinemia.
Bertolo F; De Vita S; Dolcetti R; Carbone A; Ferraccioli GF; Bartoli E; Boiocchi M
Clin Exp Rheumatol; 1999; 17(3):339-42. PubMed ID: 10410268
[TBL] [Abstract][Full Text] [Related]
14. Clincal, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis.
Sneller MC; Wang J; Dale JK; Strober W; Middelton LA; Choi Y; Fleisher TA; Lim MS; Jaffe ES; Puck JM; Lenardo MJ; Straus SE
Blood; 1997 Feb; 89(4):1341-8. PubMed ID: 9028957
[TBL] [Abstract][Full Text] [Related]
15. Autoimmune lymphoproliferative syndrome caused by a homozygous null FAS ligand (FASLG) mutation.
Magerus-Chatinet A; Stolzenberg MC; Lanzarotti N; Neven B; Daussy C; Picard C; Neveux N; Desai M; Rao M; Ghosh K; Madkaikar M; Fischer A; Rieux-Laucat F
J Allergy Clin Immunol; 2013 Feb; 131(2):486-90. PubMed ID: 22857792
[TBL] [Abstract][Full Text] [Related]
16. Next Generation Sequencing for Detecting Somatic
López-Nevado M; Docampo-Cordeiro J; Ramos JT; Rodríguez-Pena R; Gil-López C; Sánchez-Ramón S; Gil-Herrera J; Díaz-Madroñero MJ; Delgado-Martín MA; Morales-Pérez P; Paz-Artal E; Magerus A; Rieux-Laucat F; Allende LM
Front Immunol; 2021; 12():656356. PubMed ID: 33995372
[TBL] [Abstract][Full Text] [Related]
17. Fas/Apo1 mutations and autoimmune lymphoproliferative syndrome in a patient with type 2 autoimmune hepatitis.
Pensati L; Costanzo A; Ianni A; Accapezzato D; Iorio R; Natoli G; Nisini R; Almerighi C; Balsano C; Vajro P; Vegnente A; Levrero M
Gastroenterology; 1997 Oct; 113(4):1384-9. PubMed ID: 9322534
[TBL] [Abstract][Full Text] [Related]
18. Development of lymphoma in Autoimmune Lymphoproliferative Syndrome (ALPS) and its relationship to Fas gene mutations.
Poppema S; Maggio E; van den Berg A
Leuk Lymphoma; 2004 Mar; 45(3):423-31. PubMed ID: 15160902
[TBL] [Abstract][Full Text] [Related]
19. Lymphoproliferative syndrome with autoimmunity: A possible genetic basis for dominant expression of the clinical manifestations.
Rieux-Laucat F; Blachère S; Danielan S; De Villartay JP; Oleastro M; Solary E; Bader-Meunier B; Arkwright P; Pondaré C; Bernaudin F; Chapel H; Nielsen S; Berrah M; Fischer A; Le Deist F
Blood; 1999 Oct; 94(8):2575-82. PubMed ID: 10515860
[TBL] [Abstract][Full Text] [Related]
20. Immunophenotypic profiles in families with autoimmune lymphoproliferative syndrome.
Bleesing JJ; Brown MR; Straus SE; Dale JK; Siegel RM; Johnson M; Lenardo MJ; Puck JM; Fleisher TA
Blood; 2001 Oct; 98(8):2466-73. PubMed ID: 11588044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
